NCT05123365View on ClinicalTrials.gov

An Optimal Dose Finding Study of N-Acetylcysteine in Patients with Myeloproliferative Neoplasms

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 3, 2022

Primary Completion Date

July 31, 2025

Study Completion Date

November 15, 2026

Conditions
Myeloproliferative NeoplasmMPNEssential ThrombocythemiaPolycythemia VeraMyelofibrosis
Interventions
DRUG

N-Acetylcysteine

Given PO

Trial Locations (2)

92617

RECRUITING

University of California, Irvine, Irvine

92868

ACTIVE_NOT_RECRUITING

Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange

All Listed Sponsors
lead

University of California, Irvine

OTHER